S-1: Nuwellis Files for Resale of Up to 938,680 Common Shares Issuable Upon Warrant Exercise

Nuwellis, Inc. has filed a registration statement for the potential resale of up to 938,680 shares of its common stock by selling securityholders upon the exercise of warrants issued in a recent private placement.

Summary

• Nuwellis, Inc. has filed a Form S-1 registration statement with the SEC to allow selling securityholders to offer and resell up to 938,680 shares of the company's common stock.
• These shares are issuable upon the exercise of common stock purchase warrants (July Warrants) that were issued in a private placement on July 24, 2024.
• The warrants have an exercise price of $3.99 per share and expire five years from the date of issuance.
• Nuwellis will not receive any proceeds from the sale of these shares by the selling securityholders, but will receive proceeds from the exercise of any July Warrants for cash.
• The company intends to use the net proceeds from any warrant exercises for working capital and general corporate purposes.
• As of July 31, 2024, Nuwellis had 1,121,251 shares of common stock outstanding.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol NUWE, with the last reported sale price on August 13, 2024, at $2.14 per share.
• The registration statement covers the resale of a substantial number of shares, which could potentially reduce the market price of Nuwellis' common stock.
• Nuwellis is a smaller reporting company and may rely on exemptions from certain disclosure requirements.
• The selling securityholders may offer, sell, or distribute the shares in various ways and at varying prices.
• The company has agreed to file a registration statement covering the resale of the shares underlying the July Warrants as soon as practicable (and in any event within 30 days of the date of the securities purchase agreement entered into between the purchasers and us).
• We must use commercially reasonable efforts to cause such registration statement to become effective within 60 days following the closing date of the offering (or, in the event of a review by the SEC, the 90th calendar day following the closing date of the offering) and to keep such registration statement effective at all times until the purchasers no longer own any July Warrants or shares underlying the July Warrants.

Sentiment

Score: 4

Explanation: The document is primarily a registration statement for a potential resale of shares, which is generally neutral. However, the document also includes risk factors and mentions the company's past operating losses and need for additional capital, which contribute to a slightly negative sentiment.

Positives

• Nuwellis will receive proceeds if the warrants are exercised for cash, which will be used for working capital and general corporate purposes.
• The company has regained compliance with the Minimum Bid Price Requirement.

Negatives

• The resale of a substantial number of shares could reduce the market price of Nuwellis' common stock.
• The company has incurred operating losses since its inception and anticipates that it will continue to incur operating losses in the near-term.
• The company faces significant challenges in expanding market acceptance of the Aquadex System, which could adversely affect its potential sales.
• Nasdaq may delist the company's common stock from its exchange which could limit investors' ability to make transactions in its securities and subject the company to additional trading restrictions.
• The company depends on a limited number of customers, the loss of which, or failure of which to order its products in a particular period, could cause its revenues to decline.
• The company has limited commercial manufacturing experience and could experience difficulty in producing commercial volumes of the Aquadex System and related components or may need to depend on third parties for manufacturing.
• The company depends upon third-party suppliers, including single source suppliers, making it vulnerable to supply problems and price fluctuations.
• The company competes against many companies, some of which have longer operating histories, more established products and greater resources than it does, which may prevent it from achieving further market penetration or improving operating results.
• The competition for qualified personnel is particularly intense in the company's industry.
• Significant additional governmental regulation could subject the company to unanticipated delays which would adversely affect its sales.
• Product defects, resulting in lawsuits for product liability, could harm the company's business, results of operations and financial condition.
• The company may face significant risks associated with international operations, which could have a material adverse effect on its business, financial condition and results of operations.
• If the company is not able to maintain sufficient quality controls, then the approval or clearance of its products by the European Union, the FDA or other relevant authorities could be withdrawn, delayed or denied and its sales will suffer.
• If the company violates any provisions of the Federal Food, Drug, and Cosmetic Act or any other statutes or regulations, then it could be subject to enforcement actions by the FDA or other governmental agencies.
• The company cannot assure investors that its products will be safe or that there will not be serious injuries or product malfunctions.
• The company faces significant uncertainty in the industry due to government healthcare reform.
• The company is subject, directly or indirectly, to United States federal and state healthcare fraud and abuse and false claims laws and regulations.
• Failure to comply with anti-bribery, anti-corruption, and anti-money laundering laws could subject the company to penalties and other adverse consequences.
• If the company acquires other businesses, products or technologies, it could incur additional impairment charges and will be subject to risks that could hurt its business.
• The company may not be able to protect its intellectual property rights effectively, which could have an adverse effect on its business, financial condition or results of operations.
• Intellectual property litigation could be costly and disruptive to the company.
• If the company were unable to protect the confidentiality of its proprietary information and know-how, the value of its technology and system could be adversely affected.
• The company's products could infringe patent rights of others, which may require costly litigation and, if it is not successful, could cause it to pay substantial damages or limit its ability to commercialize its products.
• The company may be subject to claims that its employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• Security breaches, loss of data and other disruptions could compromise sensitive information related to its business or prevent it from accessing critical information and expose it to liability, which could adversely affect its business and its reputation.
• The trading price of the company's common stock price has been, and could continue to be, volatile.
• The rights of holders of the company's capital stock will be subject to, and could be adversely affected by, the rights of holders of its outstanding preferred stock and stock that may be issued in the future.
• A more active, liquid trading market for the company's common stock may not develop, and the price of its common stock may fluctuate significantly.
• If the company does not comply with certain tax regulations, including VAT, and similar regulations, it may be subject to additional taxes, customs duties, interest, and penalties in material amounts, which could materially harm its financial condition and operating results.
• The company's ability to use U.S. net operating loss carryforwards and other tax attributes might be limited.
• The company does not intend to pay cash dividends on its common stock in the foreseeable future.
• There may be future sales of the company's securities or other dilution of its equity, which may adversely affect the market price of its common stock.

Risks

• Sales of substantial amounts of our common stock by a Selling Securityholder or an existing securityholder, or the perception that these sales could occur, could adversely affect the price of our common stock.
• Nasdaq may delist our common stock from its exchange which could limit your ability to make transactions in our securities and subject us to additional trading restrictions.
• The company is diligently working to evidence compliance with all applicable listing criteria within the period of time granted by the Panel, but there can be no assurance that the Company will be able to do so.
• If our common stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our operations could be adversely affected.
• If our common stock is delisted from Nasdaq and it trades on the over-the-counter market at a price of less than $5.00 per share, our common stock would be considered a penny stock.
• The SEC's penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market.
• The broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and the salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account.
• In addition, the penny stock rules generally require that before a transaction in a penny stock occurs, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's agreement to the transaction.
• If applicable in the future, these rules may restrict the ability of brokers-dealers to sell our common stock and may affect the ability of investors to sell their shares, until our common stock no longer is considered a penny stock.

Future Outlook

The company expects to use the net proceeds from the exercise of any July Warrants for working capital and general corporate purposes.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors beyond stating that Nuwellis competes against many companies, some of which have longer operating histories, more established products and greater resources than it does.

Stakeholder Impact

• The potential sale of a large number of shares could reduce the market price of the common stock, impacting current shareholders.
• The company's ability to raise capital through public offerings of its securities and to finance its operations could be adversely affected if its common stock is delisted from Nasdaq.

Next Steps

• The selling securityholders will determine when and how they will dispose of the shares of common stock registered for under this prospectus for resale.
• The company is required to file its Quarterly Report on Form 10-Q for the period ending September 30, 2024, evidencing compliance with the Stockholders Equity Requirement.
• The company must use commercially reasonable efforts to cause such registration statement to become effective within 60 days following the closing date of the offering (or, in the event of a review by the SEC, the 90th calendar day following the closing date of the offering) and to keep such registration statement effective at all times until the purchasers no longer own any July Warrants or shares underlying the July Warrants.

Key Dates

Keywords

Nuwellis, common stock, warrants, resale, selling securityholders, registration statement, private placement, Aquadex, ultrafiltration, Nasdaq, NUWE, securities, offering, dilution, risk factors, SEC, filing